Nucleic Vaccine Industry Research Report 2025
Description
Summary
According to APO Research, the global Nucleic Vaccine market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Nucleic Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Nucleic Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Nucleic Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Nucleic Vaccine include CNBG, Zhifei Shengwu, Walvax Biotechnology, Sanofi, Liaoning Chengda, CanSinoBIO, BioKangtai, Hualan Bio and GSK, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nucleic Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Vaccine.
The report will help the Nucleic Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Nucleic Vaccine market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Nucleic Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Nucleic Vaccine Segment by Company
CNBG Zhifei Shengwu Walvax Biotechnology Sanofi Liaoning Chengda CanSinoBIO BioKangtai Hualan Bio GSK Fosun Pharma Moderna Inovio CureVacNucleic Vaccine Segment by Type
Preventive Nucleic Vaccine Therapeutic Nucleic VaccineNucleic Vaccine Segment by Application
Hospital Clinic OthersNucleic Vaccine Segment by Region
North America United States Canada Mexico Europe Germany France U.K. Italy Russia Spain Netherlands Switzerland Sweden Poland Asia-Pacific China Japan South Korea India Australia Taiwan Southeast Asia South America Brazil Argentina Chile Colombia Middle East & Africa Egypt South Africa Israel Türkiye GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nucleic Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nucleic Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nucleic Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Nucleic Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Nucleic Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Nucleic Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
According to APO Research, the global Nucleic Vaccine market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Nucleic Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Nucleic Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Nucleic Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Nucleic Vaccine include CNBG, Zhifei Shengwu, Walvax Biotechnology, Sanofi, Liaoning Chengda, CanSinoBIO, BioKangtai, Hualan Bio and GSK, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nucleic Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Vaccine.
The report will help the Nucleic Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Nucleic Vaccine market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Nucleic Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Nucleic Vaccine Segment by Company
CNBG Zhifei Shengwu Walvax Biotechnology Sanofi Liaoning Chengda CanSinoBIO BioKangtai Hualan Bio GSK Fosun Pharma Moderna Inovio CureVacNucleic Vaccine Segment by Type
Preventive Nucleic Vaccine Therapeutic Nucleic VaccineNucleic Vaccine Segment by Application
Hospital Clinic OthersNucleic Vaccine Segment by Region
North America United States Canada Mexico Europe Germany France U.K. Italy Russia Spain Netherlands Switzerland Sweden Poland Asia-Pacific China Japan South Korea India Australia Taiwan Southeast Asia South America Brazil Argentina Chile Colombia Middle East & Africa Egypt South Africa Israel Türkiye GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nucleic Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nucleic Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nucleic Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Nucleic Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Nucleic Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Nucleic Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Table of Contents
125 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Nucleic Vaccine Market Size (2020-2031)
- 2.2.2 Global Nucleic Vaccine Sales (2020-2031)
- 2.2.3 Global Nucleic Vaccine Market Average Price (2020-2031)
- 2.3 Nucleic Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- 2.3.2 Preventive Nucleic Vaccine
- 2.3.3 Therapeutic Nucleic Vaccine
- 2.4 Nucleic Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
- 3 Market Competitive Landscape by Manufacturers
- 3.1 Global Nucleic Vaccine Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global Nucleic Vaccine Sales (k units) of Manufacturers (2020-2025)
- 3.3 Global Nucleic Vaccine Revenue of Manufacturers (2020-2025)
- 3.4 Global Nucleic Vaccine Average Price by Manufacturers (2020-2025)
- 3.5 Global Nucleic Vaccine Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of Nucleic Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Nucleic Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Nucleic Vaccine, Established Date
- 3.9 Global Nucleic Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
- 4 Manufacturers Profiled
- 4.1 CNBG
- 4.1.1 CNBG Company Information
- 4.1.2 CNBG Business Overview
- 4.1.3 CNBG Nucleic Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 CNBG Nucleic Vaccine Product Portfolio
- 4.1.5 CNBG Recent Developments
- 4.2 Zhifei Shengwu
- 4.2.1 Zhifei Shengwu Company Information
- 4.2.2 Zhifei Shengwu Business Overview
- 4.2.3 Zhifei Shengwu Nucleic Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 Zhifei Shengwu Nucleic Vaccine Product Portfolio
- 4.2.5 Zhifei Shengwu Recent Developments
- 4.3 Walvax Biotechnology
- 4.3.1 Walvax Biotechnology Company Information
- 4.3.2 Walvax Biotechnology Business Overview
- 4.3.3 Walvax Biotechnology Nucleic Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 Walvax Biotechnology Nucleic Vaccine Product Portfolio
- 4.3.5 Walvax Biotechnology Recent Developments
- 4.4 Sanofi
- 4.4.1 Sanofi Company Information
- 4.4.2 Sanofi Business Overview
- 4.4.3 Sanofi Nucleic Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 Sanofi Nucleic Vaccine Product Portfolio
- 4.4.5 Sanofi Recent Developments
- 4.5 Liaoning Chengda
- 4.5.1 Liaoning Chengda Company Information
- 4.5.2 Liaoning Chengda Business Overview
- 4.5.3 Liaoning Chengda Nucleic Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.5.4 Liaoning Chengda Nucleic Vaccine Product Portfolio
- 4.5.5 Liaoning Chengda Recent Developments
- 4.6 CanSinoBIO
- 4.6.1 CanSinoBIO Company Information
- 4.6.2 CanSinoBIO Business Overview
- 4.6.3 CanSinoBIO Nucleic Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.6.4 CanSinoBIO Nucleic Vaccine Product Portfolio
- 4.6.5 CanSinoBIO Recent Developments
- 4.7 BioKangtai
- 4.7.1 BioKangtai Company Information
- 4.7.2 BioKangtai Business Overview
- 4.7.3 BioKangtai Nucleic Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.7.4 BioKangtai Nucleic Vaccine Product Portfolio
- 4.7.5 BioKangtai Recent Developments
- 4.8 Hualan Bio
- 4.8.1 Hualan Bio Company Information
- 4.8.2 Hualan Bio Business Overview
- 4.8.3 Hualan Bio Nucleic Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.8.4 Hualan Bio Nucleic Vaccine Product Portfolio
- 4.8.5 Hualan Bio Recent Developments
- 4.9 GSK
- 4.9.1 GSK Company Information
- 4.9.2 GSK Business Overview
- 4.9.3 GSK Nucleic Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.9.4 GSK Nucleic Vaccine Product Portfolio
- 4.9.5 GSK Recent Developments
- 4.10 Fosun Pharma
- 4.10.1 Fosun Pharma Company Information
- 4.10.2 Fosun Pharma Business Overview
- 4.10.3 Fosun Pharma Nucleic Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.10.4 Fosun Pharma Nucleic Vaccine Product Portfolio
- 4.10.5 Fosun Pharma Recent Developments
- 4.11 Moderna
- 4.11.1 Moderna Company Information
- 4.11.2 Moderna Business Overview
- 4.11.3 Moderna Nucleic Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.11.4 Moderna Nucleic Vaccine Product Portfolio
- 4.11.5 Moderna Recent Developments
- 4.12 Inovio
- 4.12.1 Inovio Company Information
- 4.12.2 Inovio Business Overview
- 4.12.3 Inovio Nucleic Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.12.4 Inovio Nucleic Vaccine Product Portfolio
- 4.12.5 Inovio Recent Developments
- 4.13 CureVac
- 4.13.1 CureVac Company Information
- 4.13.2 CureVac Business Overview
- 4.13.3 CureVac Nucleic Vaccine Sales, Revenue and Gross Margin (2020-2025)
- 4.13.4 CureVac Nucleic Vaccine Product Portfolio
- 4.13.5 CureVac Recent Developments
- 5 Global Nucleic Vaccine Market Scenario by Region
- 5.1 Global Nucleic Vaccine Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global Nucleic Vaccine Sales by Region: 2020-2031
- 5.2.1 Global Nucleic Vaccine Sales by Region: 2020-2025
- 5.2.2 Global Nucleic Vaccine Sales by Region: 2026-2031
- 5.3 Global Nucleic Vaccine Revenue by Region: 2020-2031
- 5.3.1 Global Nucleic Vaccine Revenue by Region: 2020-2025
- 5.3.2 Global Nucleic Vaccine Revenue by Region: 2026-2031
- 5.4 North America Nucleic Vaccine Market Facts & Figures by Country
- 5.4.1 North America Nucleic Vaccine Market Size by Country: 2020 VS 2024 VS 2031
- 5.4.2 North America Nucleic Vaccine Sales by Country (2020-2031)
- 5.4.3 North America Nucleic Vaccine Revenue by Country (2020-2031)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Nucleic Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Nucleic Vaccine Market Size by Country: 2020 VS 2024 VS 2031
- 5.5.2 Europe Nucleic Vaccine Sales by Country (2020-2031)
- 5.5.3 Europe Nucleic Vaccine Revenue by Country (2020-2031)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Nucleic Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Nucleic Vaccine Market Size by Country: 2020 VS 2024 VS 2031
- 5.6.2 Asia Pacific Nucleic Vaccine Sales by Country (2020-2031)
- 5.6.3 Asia Pacific Nucleic Vaccine Revenue by Country (2020-2031)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Nucleic Vaccine Market Facts & Figures by Country
- 5.7.1 South America Nucleic Vaccine Market Size by Country: 2020 VS 2024 VS 2031
- 5.7.2 South America Nucleic Vaccine Sales by Country (2020-2031)
- 5.7.3 South America Nucleic Vaccine Revenue by Country (2020-2031)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Nucleic Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Nucleic Vaccine Market Size by Country: 2020 VS 2024 VS 2031
- 5.8.2 Middle East and Africa Nucleic Vaccine Sales by Country (2020-2031)
- 5.8.3 Middle East and Africa Nucleic Vaccine Revenue by Country (2020-2031)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
- 6 Segment by Type
- 6.1 Global Nucleic Vaccine Sales by Type (2020-2031)
- 6.1.1 Global Nucleic Vaccine Sales by Type (2020-2031) & (k units)
- 6.1.2 Global Nucleic Vaccine Sales Market Share by Type (2020-2031)
- 6.2 Global Nucleic Vaccine Revenue by Type (2020-2031)
- 6.2.1 Global Nucleic Vaccine Sales by Type (2020-2031) & (US$ Million)
- 6.2.2 Global Nucleic Vaccine Revenue Market Share by Type (2020-2031)
- 6.3 Global Nucleic Vaccine Price by Type (2020-2031)
- 7 Segment by Application
- 7.1 Global Nucleic Vaccine Sales by Application (2020-2031)
- 7.1.1 Global Nucleic Vaccine Sales by Application (2020-2031) & (k units)
- 7.1.2 Global Nucleic Vaccine Sales Market Share by Application (2020-2031)
- 7.2 Global Nucleic Vaccine Revenue by Application (2020-2031)
- 7.2.1 Global Nucleic Vaccine Sales by Application (2020-2031) & (US$ Million)
- 7.2.2 Global Nucleic Vaccine Revenue Market Share by Application (2020-2031)
- 7.3 Global Nucleic Vaccine Price by Application (2020-2031)
- 8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Nucleic Vaccine Value Chain Analysis
- 8.1.1 Nucleic Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Nucleic Vaccine Production Mode & Process
- 8.2 Nucleic Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Nucleic Vaccine Distributors
- 8.2.3 Nucleic Vaccine Customers
- 9 Global Nucleic Vaccine Analyzing Market Dynamics
- 9.1 Nucleic Vaccine Industry Trends
- 9.2 Nucleic Vaccine Industry Drivers
- 9.3 Nucleic Vaccine Industry Opportunities and Challenges
- 9.4 Nucleic Vaccine Industry Restraints
- 10 Report Conclusion
- 11 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global Nucleic Vaccine Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
- Table 6. Global Nucleic Vaccine Sales (k units) of Manufacturers (2020-2025)
- Table 7. Global Nucleic Vaccine Sales Market Share by Manufacturers (2020-2025)
- Table 8. Global Nucleic Vaccine Revenue of Manufacturers (2020-2025)
- Table 9. Global Nucleic Vaccine Revenue Share by Manufacturers (2020-2025)
- Table 10. Global Market Nucleic Vaccine Average Price (US$/unit) of Manufacturers (2020-2025)
- Table 11. Global Nucleic Vaccine Industry Ranking, 2023 VS 2024 VS 2025
- Table 12. Global Manufacturers of Nucleic Vaccine, Manufacturing Sites & Headquarters
- Table 13. Global Manufacturers of Nucleic Vaccine, Product Type & Application
- Table 14. Global Nucleic Vaccine Manufacturers Established Date
- Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16. Global Nucleic Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18. CNBG Company Information
- Table 19. CNBG Business Overview
- Table 20. CNBG Nucleic Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 21. CNBG Nucleic Vaccine Product Portfolio
- Table 22. CNBG Recent Developments
- Table 23. Zhifei Shengwu Company Information
- Table 24. Zhifei Shengwu Business Overview
- Table 25. Zhifei Shengwu Nucleic Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 26. Zhifei Shengwu Nucleic Vaccine Product Portfolio
- Table 27. Zhifei Shengwu Recent Developments
- Table 28. Walvax Biotechnology Company Information
- Table 29. Walvax Biotechnology Business Overview
- Table 30. Walvax Biotechnology Nucleic Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 31. Walvax Biotechnology Nucleic Vaccine Product Portfolio
- Table 32. Walvax Biotechnology Recent Developments
- Table 33. Sanofi Company Information
- Table 34. Sanofi Business Overview
- Table 35. Sanofi Nucleic Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 36. Sanofi Nucleic Vaccine Product Portfolio
- Table 37. Sanofi Recent Developments
- Table 38. Liaoning Chengda Company Information
- Table 39. Liaoning Chengda Business Overview
- Table 40. Liaoning Chengda Nucleic Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 41. Liaoning Chengda Nucleic Vaccine Product Portfolio
- Table 42. Liaoning Chengda Recent Developments
- Table 43. CanSinoBIO Company Information
- Table 44. CanSinoBIO Business Overview
- Table 45. CanSinoBIO Nucleic Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 46. CanSinoBIO Nucleic Vaccine Product Portfolio
- Table 47. CanSinoBIO Recent Developments
- Table 48. BioKangtai Company Information
- Table 49. BioKangtai Business Overview
- Table 50. BioKangtai Nucleic Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 51. BioKangtai Nucleic Vaccine Product Portfolio
- Table 52. BioKangtai Recent Developments
- Table 53. Hualan Bio Company Information
- Table 54. Hualan Bio Business Overview
- Table 55. Hualan Bio Nucleic Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 56. Hualan Bio Nucleic Vaccine Product Portfolio
- Table 57. Hualan Bio Recent Developments
- Table 58. GSK Company Information
- Table 59. GSK Business Overview
- Table 60. GSK Nucleic Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 61. GSK Nucleic Vaccine Product Portfolio
- Table 62. GSK Recent Developments
- Table 63. Fosun Pharma Company Information
- Table 64. Fosun Pharma Business Overview
- Table 65. Fosun Pharma Nucleic Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 66. Fosun Pharma Nucleic Vaccine Product Portfolio
- Table 67. Fosun Pharma Recent Developments
- Table 68. Moderna Company Information
- Table 69. Moderna Business Overview
- Table 70. Moderna Nucleic Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 71. Moderna Nucleic Vaccine Product Portfolio
- Table 72. Moderna Recent Developments
- Table 73. Inovio Company Information
- Table 74. Inovio Business Overview
- Table 75. Inovio Nucleic Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 76. Inovio Nucleic Vaccine Product Portfolio
- Table 77. Inovio Recent Developments
- Table 78. CureVac Company Information
- Table 79. CureVac Business Overview
- Table 80. CureVac Nucleic Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 81. CureVac Nucleic Vaccine Product Portfolio
- Table 82. CureVac Recent Developments
- Table 83. Global Nucleic Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 84. Global Nucleic Vaccine Sales by Region (2020-2025) & (k units)
- Table 85. Global Nucleic Vaccine Sales Market Share by Region (2020-2025)
- Table 86. Global Nucleic Vaccine Sales by Region (2026-2031) & (k units)
- Table 87. Global Nucleic Vaccine Sales Market Share by Region (2026-2031)
- Table 88. Global Nucleic Vaccine Revenue by Region (2020-2025) & (US$ Million)
- Table 89. Global Nucleic Vaccine Revenue Market Share by Region (2020-2025)
- Table 90. Global Nucleic Vaccine Revenue by Region (2026-2031) & (US$ Million)
- Table 91. Global Nucleic Vaccine Revenue Market Share by Region (2026-2031)
- Table 92. North America Nucleic Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 93. North America Nucleic Vaccine Sales by Country (2020-2025) & (k units)
- Table 94. North America Nucleic Vaccine Sales by Country (2026-2031) & (k units)
- Table 95. North America Nucleic Vaccine Revenue by Country (2020-2025) & (US$ Million)
- Table 96. North America Nucleic Vaccine Revenue by Country (2026-2031) & (US$ Million)
- Table 97. Europe Nucleic Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 98. Europe Nucleic Vaccine Sales by Country (2020-2025) & (k units)
- Table 99. Europe Nucleic Vaccine Sales by Country (2026-2031) & (k units)
- Table 100. Europe Nucleic Vaccine Revenue by Country (2020-2025) & (US$ Million)
- Table 101. Europe Nucleic Vaccine Revenue by Country (2026-2031) & (US$ Million)
- Table 102. Asia Pacific Nucleic Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 103. Asia Pacific Nucleic Vaccine Sales by Country (2020-2025) & (k units)
- Table 104. Asia Pacific Nucleic Vaccine Sales by Country (2026-2031) & (k units)
- Table 105. Asia Pacific Nucleic Vaccine Revenue by Country (2020-2025) & (US$ Million)
- Table 106. Asia Pacific Nucleic Vaccine Revenue by Country (2026-2031) & (US$ Million)
- Table 107. South America Nucleic Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 108. South America Nucleic Vaccine Sales by Country (2020-2025) & (k units)
- Table 109. South America Nucleic Vaccine Sales by Country (2026-2031) & (k units)
- Table 110. South America Nucleic Vaccine Revenue by Country (2020-2025) & (US$ Million)
- Table 111. South America Nucleic Vaccine Revenue by Country (2026-2031) & (US$ Million)
- Table 112. Middle East and Africa Nucleic Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 113. Middle East and Africa Nucleic Vaccine Sales by Country (2020-2025) & (k units)
- Table 114. Middle East and Africa Nucleic Vaccine Sales by Country (2026-2031) & (k units)
- Table 115. Middle East and Africa Nucleic Vaccine Revenue by Country (2020-2025) & (US$ Million)
- Table 116. Middle East and Africa Nucleic Vaccine Revenue by Country (2026-2031) & (US$ Million)
- Table 117. Global Nucleic Vaccine Sales by Type (2020-2025) & (k units)
- Table 118. Global Nucleic Vaccine Sales by Type (2026-2031) & (k units)
- Table 119. Global Nucleic Vaccine Sales Market Share by Type (2020-2025)
- Table 120. Global Nucleic Vaccine Sales Market Share by Type (2026-2031)
- Table 121. Global Nucleic Vaccine Revenue by Type (2020-2025) & (US$ Million)
- Table 122. Global Nucleic Vaccine Revenue by Type (2026-2031) & (US$ Million)
- Table 123. Global Nucleic Vaccine Revenue Market Share by Type (2020-2025)
- Table 124. Global Nucleic Vaccine Revenue Market Share by Type (2026-2031)
- Table 125. Global Nucleic Vaccine Price by Type (2020-2025) & (US$/unit)
- Table 126. Global Nucleic Vaccine Price by Type (2026-2031) & (US$/unit)
- Table 127. Global Nucleic Vaccine Sales by Application (2020-2025) & (k units)
- Table 128. Global Nucleic Vaccine Sales by Application (2026-2031) & (k units)
- Table 129. Global Nucleic Vaccine Sales Market Share by Application (2020-2025)
- Table 130. Global Nucleic Vaccine Sales Market Share by Application (2026-2031)
- Table 131. Global Nucleic Vaccine Revenue by Application (2020-2025) & (US$ Million)
- Table 132. Global Nucleic Vaccine Revenue by Application (2026-2031) & (US$ Million)
- Table 133. Global Nucleic Vaccine Revenue Market Share by Application (2020-2025)
- Table 134. Global Nucleic Vaccine Revenue Market Share by Application (2026-2031)
- Table 135. Global Nucleic Vaccine Price by Application (2020-2025) & (US$/unit)
- Table 136. Global Nucleic Vaccine Price by Application (2026-2031) & (US$/unit)
- Table 137. Key Raw Materials
- Table 138. Raw Materials Key Suppliers
- Table 139. Nucleic Vaccine Distributors List
- Table 140. Nucleic Vaccine Customers List
- Table 141. Nucleic Vaccine Industry Trends
- Table 142. Nucleic Vaccine Industry Drivers
- Table 143. Nucleic Vaccine Industry Restraints
- Table 144. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. Nucleic Vaccine Product Image
- Figure 5. Global Nucleic Vaccine Revenue (US$ Million), 2020 VS 2024 VS 2031
- Figure 6. Global Nucleic Vaccine Market Size (2020-2031) & (US$ Million)
- Figure 7. Global Nucleic Vaccine Sales (2020-2031) & (k units)
- Figure 8. Global Nucleic Vaccine Average Price (US$/unit) & (2020-2031)
- Figure 9. Preventive Nucleic Vaccine Product Image
- Figure 10. Therapeutic Nucleic Vaccine Product Image
- Figure 11. Hospital Product Image
- Figure 12. Clinic Product Image
- Figure 13. Others Product Image
- Figure 14. Global Nucleic Vaccine Revenue Share by Manufacturers in 2024
- Figure 15. Global Manufacturers of Nucleic Vaccine, Manufacturing Sites & Headquarters
- Figure 16. Global Top 5 and 10 Nucleic Vaccine Players Market Share by Revenue in 2024
- Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 18. Global Nucleic Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Figure 19. Global Nucleic Vaccine Sales by Region in 2024
- Figure 20. Global Nucleic Vaccine Revenue by Region in 2024
- Figure 21. North America Nucleic Vaccine Market Size by Country in 2024
- Figure 22. North America Nucleic Vaccine Sales Market Share by Country (2020-2031)
- Figure 23. North America Nucleic Vaccine Revenue Market Share by Country (2020-2031)
- Figure 24. United States Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 25. Canada Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 26. Mexico Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 27. Europe Nucleic Vaccine Market Size by Country in 2024
- Figure 28. Europe Nucleic Vaccine Sales Market Share by Country (2020-2031)
- Figure 29. Europe Nucleic Vaccine Revenue Market Share by Country (2020-2031)
- Figure 30. Germany Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 31. France Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 32. U.K. Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 33. Italy Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 34. Russia Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 35. Spain Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 36. Netherlands Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 37. Switzerland Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 38. Sweden Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 39. Poland Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 40. Asia Pacific Nucleic Vaccine Market Size by Country in 2024
- Figure 41. Asia Pacific Nucleic Vaccine Sales Market Share by Country (2020-2031)
- Figure 42. Asia Pacific Nucleic Vaccine Revenue Market Share by Country (2020-2031)
- Figure 43. China Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 44. Japan Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 45. South Korea Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 46. India Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 47. Australia Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 48. Taiwan Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 49. Southeast Asia Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 50. Southeast Asia Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 51. South America Nucleic Vaccine Market Size by Country in 2024
- Figure 52. South America Nucleic Vaccine Sales Market Share by Country (2020-2031)
- Figure 53. South America Nucleic Vaccine Revenue Market Share by Country (2020-2031)
- Figure 54. Brazil Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 55. Argentina Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 56. Chile Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 57. Colombia Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 58. Middle East and Africa Nucleic Vaccine Market Size by Country in 2024
- Figure 59. Middle East and Africa Nucleic Vaccine Sales Market Share by Country (2020-2031)
- Figure 60. Middle East and Africa Nucleic Vaccine Revenue Market Share by Country (2020-2031)
- Figure 61. Egypt Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 62. South Africa Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 63. Israel Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 64. Türkiye Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 65. GCC Countries Nucleic Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 66. Global Nucleic Vaccine Sales Market Share by Type (2020-2031)
- Figure 67. Global Nucleic Vaccine Revenue Market Share by Type (2020-2031)
- Figure 68. Global Nucleic Vaccine Price (US$/unit) by Type (2020-2031)
- Figure 69. Global Nucleic Vaccine Sales Market Share by Application (2020-2031)
- Figure 70. Global Nucleic Vaccine Revenue Market Share by Application (2020-2031)
- Figure 71. Global Nucleic Vaccine Price (US$/unit) by Application (2020-2031)
- Figure 72. Nucleic Vaccine Value Chain
- Figure 73. Nucleic Vaccine Production Mode & Process
- Figure 74. Direct Comparison with Distribution Share
- Figure 75. Distributors Profiles
- Figure 76. Nucleic Vaccine Industry Opportunities and Challenges
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
